Revised Response Criteria for Malignant Lymphoma
Bruce D. Cheson, Beate Pfistner, Malik Eid Juweid, Randy D. Gascoyne, Lena Specht, Sandra J. Horning, Bertrand Coiffier, Richard I. Fisher, Anton Hagenbeek, Emanuele Zucca, Steven T. Rosen, Sigrid G. Stroobants, T. Andrew Lister, Richard T. Hoppe, Martin H. Dreyling, Kensei Tobinai, Julie Marie Vose, Joseph Michael Connors, Massimo Federico, Volker Diehl
Journal of Clinical Oncology · 2007 · 4,452 citationsOpen access
No retraction on record in OpenAlex.Check Crossref now
Cite this paper
Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., Rosen, S. T., Stroobants, S. G., Lister, T. A., Hoppe, R. T., Dreyling, M. H., Tobinai, K., Vose, J. M., Connors, J. M., Federico, M., & Diehl, V. (2007). Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25(5), 579–586. https://doi.org/10.1200/jco.2006.09.2403
In text: (Cheson et al., 2007)
Ask a question about this research
One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.
Abstract
PURPOSE: Standardized response criteria are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies. METHODS: The International Working Group response criteria (Cheson et al, J Clin Oncol 17:1244, 1999) were widely adopted, but required reassessment because of identified limitations and the increased use of [18F]fluorodeoxyglucose-positron emission tomography (PET), immunohistochemistry (IHC), and flow cytometry. The International Harmonization Project was convened to provide updated recommendations. RESULTS: New guidelines are presented incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma. Standardized definitions of end points are provided. CONCLUSION: We hope that these guidelines will be adopted widely by study groups, pharmaceutical and biotechnology companies, and regulatory agencies to facilitate the development of new and more effective therapies to improve the outcome of patients with lymphoma.
Related papers
- The 2016 revision of the World Health Organization classification of lymphoid neoplasms2016
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma2017
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification2014
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma2002
- Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia2002
Metadata from OpenAlex (CC0). Citations are generated from the published record.